Antimicrobial Stewardship Program

2022 Stony Brook University Hospital Antibiograms (updated 2/23/24)

Links to University Hospital's 2023 Antibiograms are below:

Stony Brook University Hospital Antibiogram (2023 data, COMMUNITY origin isolates)

Stony Brook University Hospital Antibiogram (2023 data, HOSPITAL origin isolates)

 

 

Antibiogram Notes

In general, cultures obtained from outpatients are more likely to have drug susceptible bacteria compared to cultures obtained from inpatients.  The Community antibiogram is more likely to reflect those patients seen in our clinics and those patients seen in our emergency room without recent healthcare exposures (i.e. hospitalization within the past 30 days).  This data may be more applicable to those less sick patients without risk factors for multidrug resistant pathogens. 

For patients at risk for nosocomial infections (occurring >3 days in the hospital), the Hospital based antibiogram should be used to help guide antibiotic therapy as it may better reflect the resistance patterns encountered.

The CLSI M100 reference standard is used for antibiotic breakpoints.  Based on the most recent update, some bacteria are now considered to be intrinsically resistant to antibiotics that have been previously used for treatment.  Those antibiotics for which a bacteria is considered to be intrinsically resistant are now labelled with a "R".

 

 

4/19/24

Updated Institutional Treatment Guidelines

Stony Brook Medicine Clostridioides difficile Guidelines

Stony Brook Medicine Neutropenic Fever Treatment Guidelines

Stony Brook Medicine Invasive Fungal Infection Treatment Guidelines

Stony Brook Medicine Community Acquired Bacterial Pneumonia Treatment Guidelines (updated 4/16/2024)

Stony Brook Medicine Community Acquired UTI Treatment Guidelines

2022-2023 Stony Brook Medicine COVID Treatment Guidelines

 

8/2/23

Restricted Antibiotic Standard Operating Procedure

 

 

 

 

11/18/21

U.S. Antibiotic Awareness Week: November 18-24, 2021

U.S. Antibiotic Awareness Week (USAAW) is an annual observance that highlights steps that everyone can take to improve antibiotic prescribing and use. 

The advent of antibiotics have transformed medical care, treating diseases that would otherwise be fatal and allowing for interventions not previously possible such as organ transplantations.  Antibiotics are powerful and beneficial tools in combating many infectious diseases; however, they are not without risk.  Antibiotics can be associated with medication side effects (i.e. acute kidney injury with vancomycin and piperacillin-tazobactam), disruption of the microbiome leading to Clostridioides difficile infection, and antibiotic resistance.

Antibiotic resistance is one of the most urgent threats to the public’s health.  More than 2.8 million antibiotic-resistant infections occur in the United States each year, and more than 35,000 people die as a result.  Many more die from complications from antibiotic-resistant infections.  Bacteria and fungi develop resistance in response to outside pressures such as antibiotic exposure.

Improving the way healthcare professionals prescribe antibiotics and the way people take antibiotics helps in both the short term and in the long term.  Smart antibiotic use helps ensure that our patients get the most appropriate treatment for their infections.  Over the long term, judicious use of appropriate antibiotics helps us fight the looming threat of resistance and ensure that these life-saving drugs will be available for future patients.

Test your knowledge about antibiotics by taking this survey: https://stonybrookuniversity.co1.qualtrics.com/jfe/form/SV_6PenvVghLc1qO5o

Want to learn more about the answers in the survey?  Click here. 

 

We’re proud to be a #BeAntibioticsAware partner for U.S. Antibiotic Awareness Week! Learn how you can participate: https://bit.ly/3042qDw  #BeAntibioticsAware #USAAW21

Antibiotic Awareness Week is a global event!  Join the global Twitter Storm on Thursday, November 18, from 10 AM EST – 11 AM EST.

The CDC will send out approximately 13 tweets from the @CDCgov, @CDC_NCEZID, @CDC_AR & @DrKhabbazCDC Twitter handles, starting with  "#AntibioticResistance is still a #PublicHealth threat during the #COVID19 pandemic. CDC experts are closely monitoring the possible effects of COVID-19 on the national state of AR & antibiotic use. Read more: https://bit.ly/3uISltV  #WAAW"

 

 

---

5/3/2021

Formulary updates

Stony Brook University Hospital has recently added the following antimicrobials to the formulary:

Ceftaroline

Ceftaroline is an "advanced cephalosporin" that provides coverage against both aerobic gram positive and negative bacteria.  Its spectrum of activity is similar to that of ceftriaxone (neither covers Pseudomonas or Acinetobacter species).  Ceftaroline's major advantage is that it has excellent activity against methicillin resistant Staphylococcus aureus (MRSA) by virtue of its high affinity for the PBP2a protein found in that resistant strain.

Ceftaroline is FDA approved for the treatment of community acquired pneumonia in persons without risk factors for Pseudomonas aeruginosa and skin and skin structure infection.  

 

Cefiderocol

Cefiderocol is the first of a new class of cephalosporin antibiotics: siderophore cephalosporins.  This antibiotic uses a bacteria's iron scavenging systems to evade its defense mechanisms.  Cefiderocol is active against gram-negative bacteria, including multidrug resistant organisms such as extended-spectrum beta-lactamase- and carbapenemase-producing organisms and difficult-to-treat (DTR) Pseudmonas aeruginosa.

Cefiderocol is approved by the FDA for the treatment of complicated urinary tract infections and hospital-acquired or ventilator-associated pneumonias "due to otherwise highly resistant gram-negative bacteria where there are no alternative treatment regimens."

Both Ceftaroline and Cefiderocol require a formal ID consultation for use.

---

 

---